Biogen is searching for a new CEO along with additional ways to cut costs after another quarter of paltry sales for its closely watched Alzheimer’s …
Biogen’s drug for Alzheimer’s disease, once considered a blockbuster-in-waiting, has run into so many obstacles since gaining approval last June that the company is now …
Dive Brief: Biogen has withdrawn a request to start selling its Alzheimer’s disease drug in Europe, marking the latest setback in the company’s efforts to …
Medicare will not pay for Biogen’s new Alzheimer’s medicine unless prospective patients are enrolled in a clinical trial, the U.S. government said Thursday in a …
Dive Brief: After receiving a rejection last year, Acadia said Wednesday that the Food and Drug Administration agreed to review its resubmitted application to expand …
Biogen has begun to lay off employees as part of a previously disclosed effort to lower annual expenses by half a billion dollars. The move comes …
Dive Brief: Roche is expanding clinical testing of its experimental Alzheimer’s disease drug gantenerumab, announcing Thursday the start of a late-stage trial in people with …
Dive Brief: Al Sandrock, a former top Biogen executive who led development of the company’s Alzheimer’s drug Aduhelm, is joining the board of directors at …
Biogen recorded $1 million in revenue from its new treatment for Alzheimer’s disease in the last quarter of 2021, offering the latest evidence that the …
Dive Brief: Eli Lilly is pushing back the timing for when it expects to finish submitting an application for U.S. approval of its experimental drug …
Dive Brief: The Food and Drug Administration has ordered California biotech Cortexyme to stop testing of an experimental Alzheimer’s disease drug, notifying the drugmaker in …
Medicare will restrict coverage of Biogen’s controversial Alzheimer’s treatment only to patients who take part in a rigorous clinical trial, the federal government announced Tuesday, …
The biggest industry news of the week came not from the J.P. Morgan Healthcare Conference or any associated announcements, but from Washington, D.C, where the …
Biotechnology stocks ended the first day of the J.P. Morgan Healthcare Conference in the green, but only barely. By Monday afternoon, a closely followed index of …
A crucial study evaluating Biogen’s approved drug for Alzheimer’s disease is set to begin in May, the company disclosed Thursday, and if enrollment goes as …
Diseases of the brain and central nervous system have been notoriously challenging to treat, even for the world’s largest and most well-resourced drug companies. But …
Aduhelm has come under intense scrutiny since the Food and Drug Administration’s controversial June approval of the drug, the first new Alzheimer’s treatment in decades …
The decision affects Medicare Part B, which pays for health care services typically received outside of institutional settings like hospitals and nursing homes. The planned …
Faced with the failure of a key clinical trial, a California-based biotech is pressing ahead with plans to test its experimental Alzheimer’s drug in another …
With few treatment options and millions of patients in the U.S. alone, Alzheimer’s has long been one of the biggest targets for drug developers. Yet, …
